Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms

Executive Summary

Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.

Advertisement

Related Content

Venture Funding Deals: Gene Editing Attracts Big Investors, Roivant Sets Financing Record
Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth
Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies
Robert Califf Talks Verily, Hopes Gottlieb Can Push Back On Trump
From Witty To Walmsley – The Priorities For GSK's New CEO
GSK And Google To Invest £540m In UK-Headquartered Bioelectronics JV
GSK's Vaccines Chief Slaoui To Follow Witty Out The Door
New Life Science VC Launches With €210m Fund
FINANCE ROUNDUP: Will VC Be Last Man Standing If Biotech Bubble Bursts?
Merck's $9.5bn Cubist buy overshadowed by court decision

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099520

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel